Pressure from five legislators, including Iowa Senator Chuck Grassley, to explain a steep price increase in the emergency allergic reaction treatment, EpiPen, has initiated some action. Mylan, producers of the EpiPen, announced they will expand their patient assistance programs. They have now also stated they will produce a generic version of the product for consumers. Legislators, however, are awaiting more details on the proposed plans, saying consumers, Medicare, Medicaid and insurance companies will want to know more. They are also awaiting a written response from the Food and Drug Administration (FDA) on the status of any other alternatives to the EpiPen, and what has created delays in the introduction of an alternative to the market.
